Peptide Policy Watch https://peptidepolicywatch.pages.dev/ Plain-English tracking of U.S. peptide and compounding regulation. en-us Sun, 25 Oct 2026 12:00:00 -0500 Where peptide regulation stands right now: a plain-English timelinehttps://peptidepolicywatch.pages.dev/2026/10/25/where-peptide-regulation-stands-timeline/https://peptidepolicywatch.pages.dev/2026/10/25/where-peptide-regulation-stands-timeline/Sun, 25 Oct 2026 12:00:00 -0500A plain-English timeline of peptide regulation as of October 25, 2026: what FDA documents show, what is only reported, and what is still pending. This week in peptide policy: October 19–25, 2026https://peptidepolicywatch.pages.dev/2026/10/25/weekly-quiet-week-interim-policy-pending/https://peptidepolicywatch.pages.dev/2026/10/25/weekly-quiet-week-interim-policy-pending/Sun, 25 Oct 2026 12:00:00 -0500A quiet week for official peptide and compounding actions, October 19-25, 2026, with the reported HHS interim policy still under White House review. Telehealth and compounded drugs: what the FTC and FDA have actually saidhttps://peptidepolicywatch.pages.dev/2026/10/25/telehealth-compounded-drugs-ftc-fda/https://peptidepolicywatch.pages.dev/2026/10/25/telehealth-compounded-drugs-ftc-fda/Sun, 25 Oct 2026 12:00:00 -0500What the FTC and FDA have each said about telehealth companies and compounded drugs, from public documents, and what each does not cover. FDA compounding categories explained: what Category 1 and Category 2 meanhttps://peptidepolicywatch.pages.dev/2026/10/25/fda-compounding-categories-explained/https://peptidepolicywatch.pages.dev/2026/10/25/fda-compounding-categories-explained/Sun, 25 Oct 2026 12:00:00 -0500What FDA's Category 1 and Category 2 labels for compounded bulk substances mean, and what they do not mean, using FDA's own documents.